TodayIR: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK DJ EQS-News: Zhaoke Ophthalmology Limited (6622) Successfully listed on the Main Board of SEHK EQS-News / 29/04/2021 / 12:16 UTC+8 Zhaoke Ophthalmology(6622) Successfully Listed on Main Board of SEHK [April 29, 2021, Hong Kong] Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, was successfully listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.
Zhaoke Ophthalmology is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise while designing the pipeline, the Company has initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Up to now, the Company has built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing.
TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final DJ EQS-News: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final EQS-News / 16/04/2021 / 11:26 UTC+8 Zhaoke Ophthalmology Limited (6622.HK) Launches Its HKPO with 8 Cornerstone Investors to Fuel Its Future Growth (April 16, 2021, Hong Kong) Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.
JD com To Carve-Out Its Logistics Business Via IPO forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.